26 January 2017 - The Senate finance committee's grilling this week of Tom Price, President Trump's nominee to head the Department of Health and Human Services, offered the usual combination of artful dodging and tiny scraps of information.

But sifting through the mostly non-answers revealed one interesting exchange, where Price may have cracked the door a bit on new drug-pricing policy.

Senator Ron Wyden of Oregon asked Price if he'd work with Democrats to let Medicare negotiate drug prices, something Trump recently advocated. Price suggested he was open to exploring the possibility there was a better way of doing things than the current state of affairs, in which pharmacy benefit managers do all the negotiating.

Read Bloomberg Gadfly article